The FDA has accepted for review the second resubmitted NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease.

Viatris Inc. (NASDAQ:VTRS) saw its stock drop 3.6% following news that its late-stage trial for MR-139, a potential treatment ...

Viatris's said on Friday that the trial of an ointment for people with blepharitis didn't meet its primary endpoint.

Microplastics larger than 20 µm appear to be routinely present in commercially available eye drops, according to research published in Cornea. The investigation employed the use of micro-Fourier ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

Aldeyra Therapeutics (ALDX) stock in focus as the FDA accepts its resubmitted marketing application for lead drug reproxalap ...

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax(R) Ophthalmic Suspension, 0.5%, of Bausch & ...

Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond). 2007;21 (7):968-75. 15 Taddio A, Cimaz R, Caputo R, de Libero C, Di Grande L, ...